
Illustration: Viktoria Nikolova for Endpoints News
Have sky-high sales projections set the obesity market up to fail?
Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric.
Last month, Morgan Stanley …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.